TAGRISSO 40 mg/1

TAGRISSO 40 mg film-coated tablets contain osimertinib, a medication used in cancer treatment. This prescription-only drug is manufactured by AstraZeneca Pharmaceuticals LP in the USA.

TAGRISSO is primarily used in the treatment of certain types of non-small cell lung cancer. It is often prescribed for patients with specific genetic mutations. The medication works by targeting and inhibiting the growth of cancer cells. What is TAGRISSO used for? It is typically used in advanced or metastatic stages of the disease, as determined by a healthcare provider.

Common effects of TAGRISSO may include diarrhea, rash, and fatigue. Some users may also experience nausea, dry skin, or changes in appetite. These effects can vary in intensity and duration. It is important to consult a healthcare professional for personalized advice.

TAGRISSO should be handled with care and stored as directed. It is essential to follow the prescribed dosage and administration instructions provided by a healthcare professional. Pregnant women or those planning to become pregnant should discuss the use of TAGRISSO with their doctor.

TAGRISSO may interact with certain medications, including those that are metabolized by the liver. It is important to inform your healthcare provider about all medications you are taking, including over-the-counter drugs and supplements. Alcohol consumption should be discussed with a healthcare professional.